Bronchiectasis
-
Bridging Specialties program tackles NTM pulmonary disease and bronchiectasis
CHEST launched Bridging Specialties®: Timely Diagnosis for NTM Pulmonary Disease and Bronchiectasis as a way for PCPs and pulmonologists to collaborate and provide earlier and accurate diagnoses.
-
Hope on the horizon for bronchiectasis
The combination of personalized therapies, novel and repurposed medications, and a multidisciplinary approach is transforming bronchiectasis from a condition that once had few treatment options into one that offers hope for improved management and even disease stabilization.
-
Brensocatib awaits FDA approval for bronchiectasis following ASPEN results
Experts Mark Metersky, MD, FCCP; Pamela J. McShane, MD; and Charles L. Daley, MD, FCCP, discuss the potential clinical implications of addressing inflammation in bronchiectasis—from reduced exacerbations and slowed decline in FEV to improved quality of life.
-
FDA grants clearance for SIMEOX 200 for patients with chronic lung disease
The approval offers providers an alternative to traditional airway clearance therapies for patients with chronic lung diseases such as bronchiectasis, COPD, and cystic fibrosis.
-
Pseudomonas infection in patients with noncystic fibrosis bronchiectasis
Pseudomonas aeruginosa is a clinically important organism that infects patients with noncystic fibrosis bronchiectasis (NCFB). In the United States, the estimated prevalence of NCFB is 213 per 100,000 across all […]
